Setback for Trovax in pivotal renal cancer study
This article was originally published in Scrip
Executive Summary
Oxford BioMedica's lead investigational product Trovax, a novel therapeutic cancer vaccine which is being developed with Sanofi-Aventis, will not meet its predefined primary endpoint of a survival benefit in its pivotal Phase III study in its lead indication of renal cancer, the study's data safety monitoring board advised the company after conducting a fourth interim analysis.